Legal Opinion
Mayne Pharma International Pty v. Merck Sharp & Dohme Corp.
Court of Appeals for the Federal Circuit
Decided June 21, 2019No. 2018-1593PublishedCited by 1 opinion
1Opinion of the Court
Lourie, Circuit Judge,
Mayne Pharma International Pty. Ltd. ("Mayne") appeals from the final written decision of the U.S. Patent and Trademark Office Patent Trial and Appeal Board ("the Board") in an inter partes review, concluding that claims 2, 6, and 9-14 of U.S. Patent 6,881,745 ("the '745 patent") are unpatentable as anticipated or obvious. See Merck Sharp & Dohme Corp. v. Mayne Pharma Int'l Pty. Ltd., No. IPR 2016-01186, at 2 (P.T.A.B. Dec. 18, 2017), J.A. 76-111 (" Decision "). For the reasons detailed below, we affirm.
BACKGROUND
Mayne owns the '745 patent, which discloses and claims…
2Cases cited21 opinions
- Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc.Supreme Court of the United States · 1984
- Arbaugh v. Y & H Corp.Supreme Court of the United States · 2006
- Califano v. SandersSupreme Court of the United States · 1977
- United States v. Mead Corp.Supreme Court of the United States · 2001
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
16 more not listed; retrieve them via the Exa API.
3Cited by1 opinion
- Immunex Corporation v. Sanofi-Aventis U.S. LLCCourt of Appeals for the Federal Circuit · 2020